Page last updated: 2024-12-06

cyromazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cyromazine is a broad-spectrum insect growth regulator (IGR) that disrupts the chitin synthesis in insects, leading to their death. It is used as a fungicide and insecticide. Cyromazine is synthesized by the reaction of 2-chloro-4-nitroaniline with 1,3-dichloro-2-propanone. The synthesis involves several steps, including chlorination, nitration, and amination reactions. Cyromazine is important because it is effective against a wide range of insect pests, including flies, mosquitoes, and cockroaches. It is also relatively safe for mammals and birds. Cyromazine is studied because of its effectiveness as a pest control agent and its potential for use in controlling disease vectors. Research on cyromazine focuses on its efficacy, selectivity, and environmental impact.'

cyromazine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID47866
CHEMBL ID1231107
CHEBI ID30260
SCHEMBL ID27231
MeSH IDM0092121

Synonyms (123)

Synonym
ax3 ,
n~2~-cyclopropyl-1,3,5-triazine-2,4,6-triamine
cga-72662
nsc-759268
CHEMBL1231107
cyromazine
trigard
CHEBI:30260 ,
66215-27-8
vetrazin
larvadex
cyclopropylmelamine
2,4-diamino-6-(cyclopropylamino)-s-triazine
n(2)-cyclopropyl-1,3,5-triazine-2,4,6-triamine
2-cyclopropylamino-4,6-diamino-s-triazine
n-cyclopropylmelamine
n-cyclopropyl-1,3,5-triazine-2,4,6-triamine
diamino-6-(cyclopropylamino)-s-triazine
n-cyclopropyltriazine-2,4,6-triamine
cyclopropyl-1,3,5-triazine-2,4,6-triamine
oms-2014
neporex (tn)
cyromazine (usp/inn)
D07767
n-cyclopropyl-2,4,6-triamino-1,3,5-triazine, 97%
NCGC00163803-01
ai3-52713
vetrazine
vetrazin (pesticide)
citation
armor
azimethiphos
einecs 266-257-8
cyromazinum [inn-latin]
brn 0882879
1,3,5-triazine-2,4,6-triamine, n-cyclopropyl-
neporex
cga 72662
larvadex premix
ciromazina [inn-spanish]
cypromazine
hsdb 6602
caswell no. 167b
cyromazine [ban:inn]
cyromazine [ansi:bsi:iso]
n2-cyclopropyl-1,3,5-triazine-2,4,6-triamine
NCGC00163803-02
NCGC00163803-03
AC-6858
2,4-diamino-6-(cyclopropylamino)-1,3,5-triazine
n2-cyclopropylmelamine
C2366
2-n-cyclopropyl-1,3,5-triazine-2,4,6-triamine
FT-0665421
n2-cyclopropyl-1,3,5-triazine-2,4,6-triamine;n-cyclopropyl-2,4,6-triamino-1,3,5-triazine
A835367
NCGC00163803-04
NCGC00163803-05
HMS3264K09
AKOS007930524
tox21_112074
dtxcid403999
tox21_300784
dtxsid6023999 ,
NCGC00254688-01
tox21_201846
cas-66215-27-8
NCGC00259395-01
pharmakon1600-01505903
nsc759268
S4167
unii-ca49y29ra9
cyromazinum
ciromazina
cyromazine [usp:inn:ban]
nsc 759268
ca49y29ra9 ,
n-cyclopropyl-1,3,5-triazin-2,4,6-triamine
cyromazin
n-cyclopropyl-2,4,6-triamino-1,3,5-triazine
FT-0603144
cyromazine [mi]
cyromazine [iso]
cyromazine [usp impurity]
cyromazine [inn]
cyromazine [hsdb]
cyromazine [mart.]
cyromazine [usp-rs]
CCG-213992
SCHEMBL27231
tox21_112074_1
NCGC00163803-06
CS-4864
2,4-diamino-6-cyclopropylamino-1,3,5-triazine
2,4-diamino-6-cyclopropylamino-s-triazine
2cyclopropylamino-4,6-diamino-s-triazine
Q-200914
HY-B1331
AB01563373_01
AB01563373_02
mfcd00078650
2,4-diamino-6-(cyclopropylamino)-s-triazine (8ci)
SR-01000944274-1
sr-01000944274
cyromazin, pestanal(r), analytical standard
cyromazine, united states pharmacopeia (usp) reference standard
HMS3652N03
n-cyclopropyl-1,3,5-triazine-2,4,6-triamine, 9ci
neoprex
cyromazine (inn)
SW220183-1
Q412423
cyromazine-(cyclopropyl-2,2,3,3-d4)
Z1255383207
cyromazine 100 microg/ml in acetonitrile
AS-12700
BCP13527
cyromazine (n-clopropyl-1,3,5-triazine-2,4,6-triamine)
A16473
cyromazin;cga-72662
D89506
EN300-872806
cyromazin (n-cyclopropyl- 1,3,5-triazine-2,4,6-triamine)

Research Excerpts

Overview

Cyromazine (CY) is a triazine pesticide used as an insect growth inhibitor for fly control in cattle manure, field crops, vegetables, and fruits. Cyromazine is a biorational insecticide with very low mammalian toxicity.

ExcerptReferenceRelevance
"Cyromazine is an effective, commonly-used insecticide that functions as a growth regulator, but its effect on L."( Insect hormones affect the toxicity of the insecticidal growth regulator cyromazine in Liriomyza trifolii (Diptera: Agromyzidae).
Chang, YW; Du, YZ; Gong, WR; Wang, YC; Wu, CD; Xie, HF; Yan, YQ, 2022
)
1.67
"Cyromazine (CY) is a triazine pesticide used as an insect growth inhibitor for fly control in cattle manure, field crops, vegetables, and fruits. "( Sorption of cyromazine on humic acid: Effects of pH, ionic strength and foreign ions.
Dong, YH; Lin, ZR; Zhao, L, 2014
)
2.22
"Cyromazine is a biorational insecticide with very low mammalian toxicity."( Cyromazine resistance in a field strain of house flies, Musca domestica L.: Resistance risk assessment and bio-chemical mechanism.
Akram, W; Khan, HAA, 2017
)
2.62
"Cyromazine is an effective insecticide used to control dipteran insects. "( Positional cloning of a cyromazine resistance gene in Drosophila melanogaster.
Batterham, P; Blasetti, A; Chen, Z; Daborn, PJ; Damiano, J; Heckel, D; Lumb, C; Lydall, J; McKenzie, JA; Robin, C; Smith, K, 2006
)
2.08
"Cyromazine is an insect growth regulator (IGR) insecticide that is effective against Drosophila melanogaster (Meigen). "( Cyromazine toxicity to Drosophila melanogaster (Diptera: Drosophilidae) and lack of cross-resistance in natural population strains.
Wilson, TG, 1997
)
3.18
"Cyromazine is a potent larvicide against M."( Laboratory evaluation of cyromazine against insecticide-resistant field strains of Musca domestica.
Kelly, JA; Pinniger, DB; Stubbs, MR, 1987
)
1.3

Actions

Cyromazine (CYR) can cause serious damage to the organs of animals or human beings. It was found to bind to polythymine (polyT10) via multiple hydrogen bonding interactions.

ExcerptReferenceRelevance
"Cyromazine (CYR) can cause serious damage to the organs of animals or human beings, and it was found to bind to polythymine (polyT10) via multiple hydrogen bonding interactions. "( Sensitive colorimetric detection of cyromazine in cucumber samples by using label-free gold nanoparticles and polythymine.
Bai, W; Chen, A; Liu, J; Yan, M; Yang, S; Zhu, C, 2015
)
2.13
"Cyromazine may inhibit growth or expansion of the body wall (or both) sufficiently to prevent normal internal growth, producing the observed symptoms and leading to abnormal development."( Inhibition of growth and development of tobacco hornworm (Lepidoptera: Sphingidae) larvae by cyromazine.
Dauterman, WC; Hughes, PB; Motoyama, N, 1989
)
1.22

Treatment

ExcerptReferenceRelevance
"Cyromazine seed treatments were evaluated for onion maggot control in green onion crops. "( Cyromazine seed treatments to control onion maggot, Delia antiqua, on green onions.
Hoy, CW; Yildirim, E, 2003
)
3.2

Toxicity

ExcerptReferenceRelevance
" varicornis, whereas abamectin was toxic only at concentrations substantially higher than the field rate."( Toxicity of chemicals commonly used in Indonesian vegetable crops to Liriomyza huidobrensis populations and the Indonesian parasitoids Hemiptarsenus varicornis, Opius sp., and Gronotoma micromorpha, as well as the Australian parasitoids Hemiptarsenus vari
Bjorksten, T; Hoffmann, AA; Prijono, D; Rauf, A; Robinson, M, 2004
)
0.32
"A rapid and sensitive method has been developed for the simultaneous detection of cyromazine and melamine in chicken eggs using the quick, easy, cheap, effective, rugged and safe (QuEChERS) method coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS)."( Determination of cyromazine and melamine in chicken eggs using quick, easy, cheap, effective, rugged and safe (QuEChERS) extraction coupled with liquid chromatography-tandem mass spectrometry.
Chen, CY; Chou, CC; Lee, MR; Lee, RJ; Wang, PC, 2012
)
0.94

Pharmacokinetics

ExcerptReferenceRelevance
" In order to assess the pharmacokinetic profile of CYR, chickens were administered 1 or 10 mg/kg (single oral doses), whereas residue studies were conducted in chickens fed CYR alone (5 or 10 mg/kg) or CYR (5 mg/kg) and MEL (5 mg/kg) for a period of 14 days."( Plasma pharmacokinetics and tissue depletion of cyromazine and its metabolite melamine following oral administration in laying chickens.
Chang, SK; Chou, CC; Li, KP; Ou, SC; Rairat, T; Vickroy, TW, 2017
)
0.71

Compound-Compound Interactions

ExcerptReferenceRelevance
" They show that fluorescence spectroscopy combined with SVM is efficient in predicting pesticide residue content."( Analysis of pesticide residues by a support vector machine combined with fluorescence spectroscopy.
Bian, H; Feng, X; Han, Y; Ji, R; Jiang, Z; Wang, X; Xu, J, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" The knowledge of bioavailability of a contaminant in soil can be useful to conduct environmental risk assessment."( Sorption characteristics of cyromazine and its metabolite melamine in typical agricultural soils of China.
Dong, YH; Tang, LL; Toor, G; Wang, H; Wang, HY; Zhao, L, 2014
)
0.7
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The 'square wave' type of release profile provided negligible suboptimal dosing thus limiting the potential for selection of resistance."( Intraruminal controlled release of cyromazine for the prevention of Lucilia cuprina myiasis in sheep.
Anderson, N; Jarrett, RG; Laby, RH; McKenzie, JA; Strong, MB, 1989
)
0.55
" These data indicate that dosage levels of CGA-72662 at 250 mg/kg diet produced no deleterious effects on growth, feed consumption, egg production, fertility, hatchability, livability, or progeny performance."( Effects of CGA-72662 (Larvadex) in turkeys during rearing and reproduction.
Brake, J; Campbell, WR; Ort, JF; Wages, DP, 1989
)
0.28
" Dosage concentrations of ."( Evaluation of CGA 72662 as a topical spray and feed additive for controlling house flies breeding in chicken manure.
Berry, JG; Williams, RE, 1980
)
0.26
" In fat tissues, the key genes Lep, Nmb and Nmbr were altered in high dosed offspring, and were differentially expressed between sexes."( Effects on metabolic parameters in young rats born with low birth weight after exposure to a mixture of pesticides.
Axelstad, M; Christiansen, S; Hass, U; Mandrup, K; Ramhøj, L; Svingen, T; Vinggaard, AM, 2018
)
0.48
"0229 across the dosage levels."( Evaluation of cyromazine transferred from feed to chicken products and subsequent assessment of dietary risks to Chinese consumers.
Ji, X; Lyu, W; Qian, M; Wang, J; Wang, X; Yang, H, 2020
)
0.92
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
triazine insecticidenull
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
triamino-1,3,5-triazine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
N-cyclopropylmelamine degradation08

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency0.19493.189029.884159.4836AID1224846
GLI family zinc finger 3Homo sapiens (human)Potency28.92400.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency61.64480.000221.22318,912.5098AID743035
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency8.70900.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency28.18380.000214.376460.0339AID588532
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency52.20190.003041.611522,387.1992AID1159552; AID1159553
retinoid X nuclear receptor alphaHomo sapiens (human)Potency38.18380.000817.505159.3239AID1159527; AID1159531
farnesoid X nuclear receptorHomo sapiens (human)Potency0.00500.375827.485161.6524AID588527
estrogen nuclear receptor alphaHomo sapiens (human)Potency31.92240.000229.305416,493.5996AID743069; AID743075
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency28.48670.001024.504861.6448AID743212; AID743215
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency21.82110.023723.228263.5986AID743223; AID743241
aryl hydrocarbon receptorHomo sapiens (human)Potency63.47150.000723.06741,258.9301AID743085; AID743122
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency61.644819.739145.978464.9432AID1159509
heat shock protein beta-1Homo sapiens (human)Potency48.96620.042027.378961.6448AID743210; AID743228
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (34)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (159)

TimeframeStudies, This Drug (%)All Drugs %
pre-199034 (21.38)18.7374
1990's24 (15.09)18.2507
2000's29 (18.24)29.6817
2010's53 (33.33)24.3611
2020's19 (11.95)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.82 (24.57)
Research Supply Index5.15 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index79.94 (26.88)
Search Engine Supply Index3.90 (0.95)

This Compound (30.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.18%)5.53%
Reviews1 (0.59%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other167 (98.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]